RxDoctor Payments Data

Ashima Bahl

Nurse Practitioner · Tampa, FLNPI 1477672228

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $171,349 of the $226,177 with a category attached, or 75.8%. 57 manufacturers reported payments, led by AbbVie at 50.6% of the total. Reporting peaked in 2022 at $91,016 and has fallen 84.4% since, to $14,229 in 2025. Among nurse practitioner clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$226,177in general payments, 2019–2025

Across 1,265 payments — averaging $178.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$114K
  • Biohaven Pharmaceuticals, Inc.$30K
  • Lilly USA, LLC$17K
  • Amgen$14K
  • Biohaven Pharmaceutical Holding Company Ltd.$11K
  • Lundbeck LLC$10K
  • plus $30K from 51 others

What the payments were for

  • Consulting fees$8,9574%
  • Speaking & faculty fees$171,34976%
  • Grants$850%
  • Travel & lodging$20,5419%
  • Food & beverage$24,98411%
  • Education$2610%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)343$114,352
Biohaven Pharmaceuticals, Inc.98$29,732
Lilly USA, LLC65$17,080
Amgen61$14,082
Biohaven Pharmaceutical Holding Company Ltd.40$10,536
Lundbeck LLC61$10,452
Axsome Therapeutics, Inc.28$7,487
Impel Pharmaceuticals Inc.31$5,296
Impel Pharmaceuticals LLC9$3,898
Teva Pharmaceuticals USA, Inc.60$3,451
Jazz Pharmaceuticals Inc.42$1,152
Pfizer69$950
UCB, Inc.40$799
SK Life Science, Inc.28$759
Eisai Inc.36$724
Otsuka America Pharmaceutical, Inc.27$519
Upsher-smith Laboratories LLC21$519
Neurocrine Biosciences, Inc.19$365
Acadia Pharmaceuticals Inc14$336
Scilex Pharmaceuticals Inc.14$310
Avanir Pharmaceuticals, Inc.14$268
Argenx US, Inc.13$265
Harmony Biosciences LLC12$253
Kyowa Kirin, Inc.11$239
Amneal Pharmaceuticals LLC10$209
Acorda Therapeutics, Inc7$167
Janssen Scientific Affairs, LLC1$149
Merz Pharmaceuticals, LLC6$140
Sunovion Pharmaceuticals Inc.7$127
Sumitomo Pharma America, Inc.7$122
Sanofi1$115
Neurelis, Inc.6$115
GE HealthCare5$106
MDD US Operations, LLC5$106
Azurity Pharmaceuticals, Inc.4$82
Novartis4$82
Currax Pharmaceuticals LLC5$78
Almatica Pharma LLC4$74
Avion Pharmaceuticals4$74
AstraZeneca(2 entities)4$71
Collegium Pharmaceutical, Inc.4$64
Supernus Pharmaceuticals, Inc.4$60
Takeda Pharmaceuticals U.S.A., Inc.2$52
Arbor Pharmaceuticals, Inc.3$51
Adamas Pharmaceuticals, Inc.3$49
Genentech USA, Inc.2$32
TG Therapeutics, Inc.1$29
Catalyst Pharmaceuticals, Inc.1$24
Nevro Corp.1$24
Merck1$23
C2n Diagnostics, LLC1$20
Boston Scientific1$19
Tonix Medicines, Inc.1$19
Vanda Pharmaceuticals Inc.1$18
Johnson & Johnson1$16
Idorsia Pharmaceuticals US Inc1$16
Inspire Medical Systems, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$226,177 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$246,275
Medicare patients
266
Services billed
27,644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate91$169,876
QuliptaAtogepant120$152,839
UbrelvyUbrogepant80$141,573
Aimovig AutoinjectorErenumab-Aooe97$90,022
NuplazidPimavanserin Tartrate11$58,573
GocovriAmantadine Hcl13$43,757
Emgality PenGalcanezumab-Gnlm50$40,776
ZavzpretZavegepant Hcl14$24,337
Keppra XrLevetiracetam12$7,399
Diclofenac Potassium15$5,863
Dihydroergotamine Mesylate11$5,610
Sumatriptan Succinate61$4,104
Lamotrigine ErLamotrigine14$3,347
Levetiracetam63$3,284
FingolimodFingolimod Hcl13$2,777

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$114,352$294,412200 claims
PfizerNurtec Odt, Zavzpret$950$194,213105 claims
Acadia Pharmaceuticals IncNuplazid$336$58,57311 claims
MDD US Operations, LLCGocovri$106$43,75713 claims
Upsher-smith Laboratories LLCTopiramate$519$93273 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →